PD-L1 expressing circulating tumour cells in head and neck cancers.
Arutha KulasingheChris PerryLiz KennyMajid E WarkianiColleen NelsonChamindie PunyadeeraPublished in: BMC cancer (2017)
This report highlights the potential use of CTCs to identify patients which might respond to anti PD-L1 therapy.